Laure Favier - Concepedia

Author

Laure Favier

Centre Georges François Leclerc

Also Known As

Coraline Dubot, L Favier, L. Favier, LAURE FAVIER, Laure Favier, Lea Favier, M Falcon, M. Elder, Michel Fabbro

173

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Centre Georges François Leclerc Inserm Centre Léon Bérard Institut Gustave Roussy Université de Bourgogne

About

Laure Favier is an author at Centre Georges François Leclerc specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	922
2	Health Sciences	2	2	58
3	Engineering	1	1	29
4	Cell Biology	1	1	199
5	Chemistry	1	1	37

Laure Favier

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Tumor cells can escape DNA‐damaging cisplatin through DNA endoreduplication and reversible polyploidy Pierre‐Emmanuel Puig, Marie‐Noëlle Guilly, André Bouchot, Cell Biology International	2008	254
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells Emeric Limagne, Lisa Nuttin, Marion Thibaudin, Cancer Cell Cancer ImmunosurveillanceOncologyMedicineImmunologyImmune Checkpoint Inhibitor	2022	199
Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients Emeric Limagne, Corentin Richard, Marion Thibaudin, OncoImmunology Secondary ResistancesPd-1 BlockadeImmunologyImmunoeditingPathology	2019	198
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations Julien Mazières, Claire Cropet, Laure Montané, Annals of Oncology	2020	185
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy Jean-David Fumet, Corentin Richard, Fanny Ledys, British Journal of Cancer	2018	169
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial Sandro Pignata, Domenica Lorusso, Florence Joly, The Lancet Oncology Carboplatin-based DoubletMedicineMetronomic TherapyGynecologyPlatinum-sensitive Ovarian Cancer	2021	144
Antibiotic Use Does Not Appear to Influence Response to Nivolumab Courèche Kaderbhaï, Corentin Richard, Jean David Fumet, Anticancer Research	2017	106
Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study Ignace Vergote, Antonio Jimeno, Florence Joly, Journal of Clinical Oncology	2013	105
Monitoring HSP70 exosomes in cancer patients’ follow up: a clinical prospective pilot study Gaëtan Chanteloup, Marine Cordonnier, Nicolás Isambert, Journal of Extracellular Vesicles	2020	105
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO Isabelle Ray‐Coquard, Laure Favier, B. Weber, British Journal of Cancer	2013	102

Page 1